肝纤维化标志物可预测Fontan相关肝病发生
这项回顾性多中心研究纳入137例2004至2020年间接受Fontan手术且随访至少3年的患者,评估纤维化-4指数(FIB-4)、AST/PLT比值指数和MELD-excluding INR评分对Fontan相关肝病(FALD)早期预测的价值。结果表明Fontan术后2年测得的FIB-4是10年后发生FALD的强预测因子,且FIB-4>0.17者10年后FALD发生率显著高于≤0.17者(45.6% vs 3.9%,P=0.002),这些患者5年后肺动脉压力也更高。
要点
- Fontan术后2年FIB-4可预测10年后FALD发生(AUC 0.81,截断值0.17)。
- FIB-4>0.17者10年后FALD发生率为45.6%,显著高于≤0.17者的3.9%。
- FIB-4>0.17者5年后肺动脉压力更高。
核心结论
- FIB-4可能是早期检测Fontan相关肝病的有用标志物,且在该研究中被确定为FALD发生的危险因素。
研究设计与样本
- 回顾性多中心研究,纳入2004至2020年间接受Fontan手术且随访至少3年的患者,共137例。
- 通过血液检查和影像学诊断Fontan相关肝病,采用受试者工作特征曲线分析评估标志物预测价值,采用Fine-Gray竞争风险分析识别危险因素。
主要发现
- Fontan术后2年测得的FIB-4是10年后FALD发生的强预测因子(AUC 0.81,最佳截断值0.17,灵敏度83.1%,特异度73.0%)。
- Fine-Gray分析显示FIB-4水平是FALD发生的关键危险因素。
- 术后2年FIB-4>0.17者10年后FALD发生率为45.6%,显著高于FIB-4≤0.17者的3.9%(P=0.002)。
- FIB-4>0.17者5年后肺动脉压力更高。
关键数值与推荐
- FIB-4预测10年后FALD的AUC为0.81,最佳截断值0.17,灵敏度83.1%,特异度73.0%。
- FIB-4>0.17者10年后FALD发生率为45.6%,FIB-4≤0.17者为3.9%(P=0.002)。
临床怎么用
- Fontan术后2年可检测FIB-4,若>0.17提示10年后FALD发生风险较高,需加强随访监测。
- FIB-4>0.17的患者5年后肺动脉压力更高,应关注血流动力学评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate how well liver fibrosis markers (fibrosis-4 index, aspartate aminotransferase to platelet ratio index, and model for end-stage liver disease excluding international normalized ratio score) can predict early detection of Fontan-associated liver disease and to identify risk factors for Fontan-associated liver disease development. METHODS: This retrospective multicentre study included patients who underwent the Fontan procedure between 2004 and 2020 with at least 3 years of follow-up. Blood tests and imaging were conducted to diagnose Fontan-associated liver disease. The predictive value of these markers was assessed using receiver operating characteristic curve analysis. Risk factors for Fontan-associated liver disease development were identified using Fine-Gray subdistribution hazard analysis. RESULTS: This study included 137 patients. The fibrosis-4 index, measured at 2 years post-Fontan, was a strong predictor for Fontan-associated liver disease development 10 years later (area under the curve: 0.81, optimal cutoff value: 0.17, 83.1% sensitivity, and 73.0% specificity). Fine-Gray subdistribution hazard analysis shows that a fibrosis-4 index level was a key risk factor for Fontan-associated liver disease. Patients with a fibrosis-4 index >0.17 after 2 years had a higher incidence of Fontan-associated liver disease after 10 years (45.6%) than patients with fibrosis-4 index ≤0.17 (3.9%, P = 0.002). These patients also had higher pulmonary artery pressure 5 years later. CONCLUSIONS: The fibrosis-4 may be a useful marker for early detection of Fontan-associated liver disease, which, in this study, was identified as a risk factor for the disease's development. CLINICAL REGISTRATION NUMBER: Kitasato University, No. B23-130; 7 February 2024.
引用
- Horie S, Shikata F, Oka N, et al. Liver fibrosis marker is a potential predictor of the development of Fontan-associated liver diseases†. Eur J Cardiothorac Surg. 2025. PMID: 40131395. doi:10.1093/ejcts/ezaf100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。